Nature Communications (Oct 2021)
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis
- Jeannine Diesch,
- Marguerite-Marie Le Pannérer,
- René Winkler,
- Raquel Casquero,
- Matthias Muhar,
- Mark van der Garde,
- Michael Maher,
- Carolina Martínez Herráez,
- Joan J. Bech-Serra,
- Michaela Fellner,
- Philipp Rathert,
- Nigel Brooks,
- Lurdes Zamora,
- Antonio Gentilella,
- Carolina de la Torre,
- Johannes Zuber,
- Katharina S. Götze,
- Marcus Buschbeck
Affiliations
- Jeannine Diesch
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Marguerite-Marie Le Pannérer
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- René Winkler
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Raquel Casquero
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Matthias Muhar
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC)
- Mark van der Garde
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München
- Michael Maher
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Carolina Martínez Herráez
- Laboratory of Cancer Metabolism, ONCOBELL Program, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
- Joan J. Bech-Serra
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Michaela Fellner
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC)
- Philipp Rathert
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC)
- Nigel Brooks
- CellCentric, Ltd, Chesterford Research Park
- Lurdes Zamora
- Hematology Laboratory Service, ICO Badalona‐Hospital Germans Trias I Pujol, Josep Carreras Leukemia Research Institute (IJC)
- Antonio Gentilella
- Laboratory of Cancer Metabolism, ONCOBELL Program, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
- Carolina de la Torre
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- Johannes Zuber
- Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC)
- Katharina S. Götze
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München
- Marcus Buschbeck
- Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC)
- DOI
- https://doi.org/10.1038/s41467-021-26258-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Azacitidine (AZA) treatment is used for patients with myelodysplasias that cannot undergo bone marrow transplantation; however, AZA treatment is only partially effective. Here the authors show synergy of AZA with compounds inhibiting the chromatin regulators CBP and p300, which is mediated by the RNA-dependent functions of AZA affecting protein translation.
